Literature DB >> 18508371

Polysomnographic values in adolescents with ataxia telangiectasia.

Sharon A McGrath-Morrow1, Laura Sterni, Brian McGinley, Maureen A Lefton-Greif, Karen Rosquist, Howard Lederman.   

Abstract

Most adolescents with ataxia telangiectasia (A-T) develop progressive bulbar muscle weakness and decreased pulmonary reserve. The purpose of this study was to define the patterns of sleep and respiration during sleep, and to identify sleep-related breathing problems in subjects with A-T. To address these issues, overnight polysomnography was performed on 12 adolescents with A-T. Eleven of the 12 subjects completed overnight polysomnography. The median age was 16 years (range, 13-20 years). All subjects in the study were wheelchair-bound and the median forced vital capacity (% predicted of normal) was 44% (range, 16-82%). The mean sleep efficiency was 72.6% with a mean apnea hypopnea index (AHI) of 0.7 events/hr (range, 0-2.2). The majority of apnea/hypopneas were REM related. The mean central apnea index was 0.1 events/hr (range, 0-0.2). The mean oxygen saturation nadir was 92.7% (range, 87-96) and the mean peak end-tidal carbon dioxide ET(CO(2) ) value was 53.8 mm Hg (range, 49-60). Two of 11 subjects had ET(CO(2) ) values >or=50 mm Hg for more than 50% of total sleep time. In this study, the majority of A-T adolescents had infrequent partial or complete upper airway obstructions during sleep and minimal nighttime hypoxemia. They did, however, have decreased sleep efficiency most likely, due in part, to their underlying neurological condition. This decrease in total sleep time may underestimate hypoventilation. Based on these findings, overnight polysomnography should be considered in adolescents with A-T, particularly in those in which there is a clinical suspicion of sleep related breathing abnormalities.

Entities:  

Mesh:

Year:  2008        PMID: 18508371     DOI: 10.1002/ppul.20838

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

1.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

Review 2.  Sleep-disordered breathing in neurodegenerative diseases.

Authors:  Carles Gaig; Alex Iranzo
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

Review 3.  Executive summary of respiratory indications for polysomnography in children: an evidence-based review.

Authors:  Merrill S Wise; Cynthia D Nichols; Madeleine M Grigg-Damberger; Carole L Marcus; Manisha B Witmans; Valerie G Kirk; Lynn A D'Andrea; Timothy F Hoban
Journal:  Sleep       Date:  2011-03-01       Impact factor: 5.849

4.  Practice parameters for the respiratory indications for polysomnography in children.

Authors:  R Nisha Aurora; Rochelle S Zak; Anoop Karippot; Carin I Lamm; Timothy I Morgenthaler; Sanford H Auerbach; Sabin R Bista; Kenneth R Casey; Susmita Chowdhuri; David A Kristo; Kannan Ramar
Journal:  Sleep       Date:  2011-03-01       Impact factor: 5.849

Review 5.  Sleep Disorders in Hereditary Ataxias.

Authors:  Lucio Huebra; Fernando Morgadinho Coelho; Flávio Moura Rezende Filho; Orlando G Barsottini; José Luiz Pedroso
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-25       Impact factor: 5.081

Review 6.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

7.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.